Premium
Nutrient Support in Hematopoietic Cell Transplantation
Author(s) -
Lenssen Polly,
Bruemmer Barbara,
Aker Saundra N.,
McDonald George B.
Publication year - 2001
Publication title -
journal of parenteral and enteral nutrition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.935
H-Index - 98
eISSN - 1941-2444
pISSN - 0148-6071
DOI - 10.1177/0148607101025004219
Subject(s) - medicine , hematopoietic cell , hematopoietic stem cell transplantation , haematopoiesis , transplantation , disease , parenteral nutrition , graft versus host disease , oncology , stem cell , surgery , biology , genetics
High‐dose cytoreduction and hematopoietic stem cell infusion form the basis for treatment of hematologic cancers, defects or failure of hematopoiesis, and some solid tumors. As an antitumor therapy, allogeneic hematopoietic cell transplantation (HCT) is superior to autologous HCT by induction of a graft‐ us ‐tumor effect. However, recipients of allografts suffer higher transplant‐related mortality owing to graft‐ us ‐host disease (GVHD). Nutrition support research must recognize that HCT is a heterogeneous modality whose short and long‐term outcomes are affected by transplant type, preparative regimens, diagnosis, disease stage, age, and nutritional status. The field of HCT will diversify further as lower dose cytoreduction and mixed chimerism grafts allow expansion of the technique to older patients and to other diseases. (journal of Parenteral and Enteral Nutrition 25:219–228, 2001)